Halozyme Therapeutics (HALO) Non-Current Debt (2012 - 2026)

Halozyme Therapeutics (HALO) has 15 years of Non-Current Debt data on file, last reported at $1.9 billion in Q1 2026.

• On a quarterly basis, Non-Current Debt rose 28.42% year-over-year to $1.9 billion in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 28.42% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, up 42.29% from the prior year.
• Non-Current Debt for Q1 2026 stood at $1.9 billion, down from $2.1 billion in the prior quarter.
• Over the last five years, Non-Current Debt for HALO reached as high as $2.1 billion in Q4 2025 and fell as low as $788.1 million in Q1 2022.
• Historically, Non-Current Debt has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2024.
• Across the five-year window, Non-Current Debt soared 91.31% in 2022 and sank 46.81% in 2025, its largest moves.
• Year by year, Non-Current Debt stood at $1.5 billion in 2022, then dropped by 0.45% to $1.5 billion in 2023, then gained by 0.44% to $1.5 billion in 2024, then jumped by 42.29% to $2.1 billion in 2025, then slipped by 9.65% to $1.9 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $1.9 billion in Q1 2026, $2.1 billion in Q4 2025, and $800.1 million in Q3 2025.